Literature DB >> 12649387

Piribedil enhances frontocortical and hippocampal release of acetylcholine in freely moving rats by blockade of alpha 2A-adrenoceptors: a dialysis comparison to talipexole and quinelorane in the absence of acetylcholinesterase inhibitors.

A Gobert1, B Di Cara, L Cistarelli, M J Millan.   

Abstract

In a dialysis procedure not requiring perfusate addition of acetylcholinesterase inhibitors to "boost" basal levels of acetylcholine (ACh), the influence of the antiparkinson agent piribedil upon levels of ACh in frontal cortex and dorsal hippocampus of freely moving rats was compared with those of other antiparkinson drugs and selective ligands at alpha(2)-adrenoceptors (ARs). Suggesting a tonic, inhibitory influence of alpha(2A)-ARs upon cholinergic transmission, the alpha(2)-AR agonist 5-bromo-6-[2-imidazolin-2-yl-amino]-quinoxaline tartrate (UK14,304), and the preferential alpha(2A)-AR agonist guanabenz reduced levels of ACh. They were elevated by the antagonists 2(2-methoxy-1,4 benzodioxan-2-yl)-2-imidazoline HCl (RX821002) and atipamezole and by the preferential alpha(2A)-AR antagonist 2-(2H-(1-methyl-1,3-dihydroisoindole)methyl)-4,5-dihydroimidazole (BRL44008). In contrast, trans-2,3,9,13b-tetrahydro-1,2-dimethyl-1H-dibenz[c,f]imidazo[1,5-a]azepine (BRL41992) and prazosin, preferential alpha(2B/2C)-AR antagonists, were inactive. The dopaminergic agonist and antiparkinson agent piribedil, which behaves as an antagonist at alpha(2)-ARs, dose dependently increased extracellular levels of ACh. This action was absent upon pretreatment with a maximally effective dose of RX821002. On the other hand, a further dopaminergic agonist and antiparkinson agent, talipexole, which possesses agonist properties at alpha(2)-ARs, dose dependently reduced levels of ACh. This action was also blocked by RX821002. In contrast to piribedil and talipexole, quinelorane, which interacts with dopaminergic receptors but not alpha(2)-ARs, failed to affect ACh levels. Finally, in analogy to the frontal cortex, piribedil likewise elicited a dose-dependent increase in extracellular levels of ACh in the dorsal hippocampus. In conclusion, in distinction to talipexole and quinelorane, and reflecting its antagonist properties at alpha(2A)-ARs, piribedil reinforces cholinergic transmission in the frontal cortex and dorsal hippocampus of freely moving rats. These actions may be related to its facilitatory influence upon cognitive function.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12649387     DOI: 10.1124/jpet.102.046383

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  10 in total

1.  Efficient measurement of endogenous neurotransmitters in small localized regions of central nervous systems in vitro with HPLC.

Authors:  Xuesi M Shao; Jack L Feldman
Journal:  J Neurosci Methods       Date:  2006-11-07       Impact factor: 2.390

Review 2.  The potential role of dopamine D₃ receptor neurotransmission in cognition.

Authors:  Shinichiro Nakajima; Philip Gerretsen; Hiroyoshi Takeuchi; Fernando Caravaggio; Tiffany Chow; Bernard Le Foll; Benoit Mulsant; Bruce Pollock; Ariel Graff-Guerrero
Journal:  Eur Neuropsychopharmacol       Date:  2013-06-20       Impact factor: 4.600

3.  Trace Amine-Associated Receptor 1 Contributes to Diverse Functional Actions of O-Phenyl-Iodotyramine in Mice but Not to the Effects of Monoamine-Based Antidepressants.

Authors:  Ioannis Mantas; Mark J Millan; Benjamin Di Cara; Lucianne Groenink; Sylvie Veiga; Laetitia Cistarelli; Mauricette Brocco; Marc Bertrand; Per Svenningsson; Xiaoqun Zhang
Journal:  Int J Mol Sci       Date:  2021-08-18       Impact factor: 5.923

4.  Alpha2-adrenoceptor blockade accelerates the neurogenic, neurotrophic, and behavioral effects of chronic antidepressant treatment.

Authors:  Sudhirkumar U Yanpallewar; Kimberly Fernandes; Swananda V Marathe; Krishna C Vadodaria; Dhanisha Jhaveri; Karen Rommelfanger; Uma Ladiwala; Shanker Jha; Verena Muthig; Lutz Hein; Perry Bartlett; David Weinshenker; Vidita A Vaidya
Journal:  J Neurosci       Date:  2010-01-20       Impact factor: 6.167

Review 5.  Piribedil for the Treatment of Motor and Non-motor Symptoms of Parkinson Disease.

Authors:  Santiago Perez-Lloret; Olivier Rascol
Journal:  CNS Drugs       Date:  2016-08       Impact factor: 5.749

Review 6.  Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs.

Authors:  Mark J Millan
Journal:  Neurotherapeutics       Date:  2009-01       Impact factor: 7.620

7.  Characterization of the effects of receptor-selective ligands in rats discriminating the novel antipsychotic quetiapine.

Authors:  Andrew J Goudie; Judith A Smith; Mark J Millan
Journal:  Psychopharmacology (Berl)       Date:  2003-09-24       Impact factor: 4.530

8.  1-Piperonylpiperazinium 4-nitro-benzoate monohydrate.

Authors:  Channappa N Kavitha; Manpreet Kaur; Brian J Anderson; Jerry P Jasinski; H S Yathirajan
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2014-02-12

9.  1-Piperonylpiperazinium 4-chloro-benzoate.

Authors:  Channappa N Kavitha; Manpreet Kaur; Brian J Anderson; Jerry P Jasinski; H S Yathirajan
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2014-02-12

10.  Opposing effects of α2- and β-adrenergic receptor stimulation on quiescent neural precursor cell activity and adult hippocampal neurogenesis.

Authors:  Dhanisha J Jhaveri; Ishira Nanavaty; Boris W Prosper; Swanand Marathe; Basma F A Husain; Steven G Kernie; Perry F Bartlett; Vidita A Vaidya
Journal:  PLoS One       Date:  2014-06-12       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.